Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The news is newsing hard these days, no?
China hits the brakes on controversial trials
China’s fast, cheap route to human testing is getting considerably less speedy. New government restrictions and news of recent patient deaths have slowed investigator-initiated trials, or IITs, STAT’s Jason Mast reports. This is perhaps to the chagrin of U.S. biotechs eager to bypass lengthy development timelines.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source: www.statnews.com
